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SUMMARY : Antibiotic activities of the Bacillus subtilis DB9011 culture supernatant extracts
against 52 pathogenic microbes were screened by measuring the zone of growth inhibition of
the pathogens under a sterile paper disc loaded with the supernatant extract. The first
scientific evidence for the effectiveness of the DB9011 culture extract against Porphyromonas
gingivalis, Clostridium difficile, Propionibacterium acnes, and Legionella pneumophila is
presented here. These organisms are causative pathogens of periodontal disease, Clostridium
difficile-associated colitis, acne, and pneumonia, respectively. The findings from the present
study will contribute to the development of more efficacious and safer pharmacotherapeutic
agents for these diseases.
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INTRODUCTION
Since the advent of the antibiotic, bacitracin, in
19431) different strains of Bacillus subtilis (B.
subtilis) have provided a good source for a variety of
antibiotics and other pharmaceuticals.2-6)
Furthermore, B. subtilis culture itself has been used
widely for dietary supplements for human, livestock,
and poultry.7-10) In fact the widely consumed,
centuries old Japanese delicatessen/health food,
Natto, is composed of odoriferous, sticky fermented
soybeans prepared by means of one of the many B.
subtilis strains, commonly known as Bacillus natto.
Historically purported human health benefits of Natto
include growth promotion and curing of intestinal
diseases, gingivitis, heart diseases and a few more. 
Not long after the Typhoid Mary incident in the
U.S., Japanese investigators reported that feeding the
Typhoid patients Natto eradicated completely the
causative pathogen, Salmonella Paratyphi B, from the
human intestinal tracts.11),12) Scientific reports in
support of some of the purported human health
benefits are appearing in both Japanese and Western
scientific journals in recent years.13-17) Furthermore,
the efficacy and safety of B. subtilis cultures and
subtherapeutic doses of antibiotics from the culture
as a growth promoter have been reported.3),18),19) In
Japan, the safety of B. subtilis culture for human
consumption was recognized based on the long
experience with Natto. In the U.S., on the other hand,
the U.S. Environment Protection Agency (EPA)
assessment defined that  B. subtilis strains as a group
are benign organisms as they do not possess traits
that cause disease.20)
B. subtilis DB9011 was isolated from Japanese soil
in 1990,4) and provided a good source for the
production of antibiotics and other
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pharmaceuticals.3),4) However, the full potential for
production of novel antibiotics has not been explored.
This report describes a thorough assessment of a
broad range of antibiotic spectrum found in the
DB9011 culture supernatant, giving particular
attention to the historically purported human health
benefits of B. subtilis and products derived from it.
MATERIALS AND METHODS
DB9011 cells were grown on Mueller-Hinton agar
plate (MHA, Eiken Chemicals, Tokyo), and a single
colony was inoculated into Mueller-Hinton broth
(MHB, Difco, USA). The flask was incubated
aerobically at 35℃ on a rotator shaker at 200 rpm for
desired time periods, which were dependent upon the
purpose of each preparation. The cells were removed
by centrifugation at 15,000 rpm for 15 min, and the
supernatant was filtered through a 0.45 μm filter
(Advantec. Tokyo).
The filtered DB9011 supernatant was mixed with 1
N HCl until the pH reached 3.0. The precipitated
material was separated by centrifugation for 10 min at
15,000 rpm. The active component was extracted by
solubilizing the pellet in an aliquot of 80% ethanol to
obtain 300-fold concentrated supernatant solution (300
x extract).
The following preliminary experiments were
performed in order to establish the rationale for
choosing DB9011 and the rest of the experimental
protocols. Porphyromonas gingivalis JCM 8525 (P.
gingivalis)---the strain that had been shown as the
main causative agent of periodontal diseases 21)---was
used as the test strain for the determination of
optimum condition for the antibiotic production by
DB9011. In this series of experiments 20 μl of the
filtered DB9011 supernatant were used for the
determination of zone of growth inhibition (ZOGI)22-24).
The time course of anti-P. gingivalis activity during
the DB9011 growth period showed that the activity
peaked during the stationary phase at the 24th hour
after the inoculation, and thereafter the activity
declined gradually during the 48 h growth period.
Table 1：Summary of test strain culture conditions
79
Therefore the antibiotic activities of 4 other
commonly available B. subtilis strains that consisted
of ATCC6633, BN1001, KUBOTA, and OUV23481
were compared with that of DB9011. Under the
conditions of the experiments the ZOGI of DB9011
was 25 mm in diameter whereas that of ATCC6633
was 10 mm and others were equal to or less than 8
mm.
The antibiotic activities of the 300 x extract of
DB9011 against 52 test strains of potential pathogens
were assayed using specific agar medium and growth
conditions appropriate for each test strain.25,26) The
conditions of each test strain culture are codified and
summarized in Table 1.
RESULTS AND DISCUSSION
Table 2 shows the antibiotic activities assay results.
Anaerobic organisms seemed to be more frequently
susceptible than those in other groups. Common
nosocomial pathogens in the aerobic and facultative
anaerobic group seemed less susceptible to the active
component of the 300 x extract than those in the
anaerobic group. Furthermore, it is interesting to note
that the potent antibiotic activity of B. subtilis
DB9011 extract against P. gingivalis shown in this
study is - consistent with the purported effectiveness
of Natto, the Japanese delicatessen referred,7-12)
earlier.  Our findings also corroborate the pre-
antibiotic era Japanese investigators’ reports 11),12)
concerning the effectiveness of a Natto diet for
eradicating intestinal Samonella Paratyphi B.
Among the organisms most sensitive to the 300 x
extract were P. gingivalis, C. difficile, L.
pneumophila, and P. acnes. Currently, there are no
satisfactory pharmacotheraputic regimens to treat
the periodontal disease caused by P. gingivalis.21)
Clostridium difficile-associated colitis can be lethal,
and the drugs of choice are vancomycin and
metronidazole. These antibiotics are produced from
Streptomyces orientalis (Amylcolaptosis orientalis)
and by the organic chemical synthesis method,
respectively. This observation suggested that the
Table 2：Suscetibility of pathogens to 300 x extract of DB9011 culture supernatant
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anti-P. gingivalis component in the DB9011 culture
extract could be a novel vancomycin-like antibiotic.
The search for new, more efficacious and safer
antibiotics is always needed in preparation for the
emergence of antibiotic resistant strains.
The recent reports concerning the mechanisms,
efficacy, and safety of B. subtilis culture and the
products derived from the culture for human health
benefits cited here13-19) together with the findings in
this report suggest that the anti-P. gingivalis, -C.
difficile; -L. pneumonia, and -P. acnes substances
described here are likely novel,  efficacious, and safer
pharmacotherapeutic agents.
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